Nucleic acid-controlled catalytic rnas for trigger-responsive regulation
US-2024425855-A1 · Dec 26, 2024 · US
Peptide-based in vivo siRNA delivery system
US9526796B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9526796-B2 |
| Application number | US-201514789142-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 1, 2015 |
| Priority date | Dec 17, 2010 |
| Publication date | Dec 27, 2016 |
| Grant date | Dec 27, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention is directed compositions for targeted delivery of RNA interference (RNAi) polynucleotides to hepatocytes in vivo. Targeted RNAi polynucleotides are administered together with co-targeted melittin delivery peptides. Delivery peptides provide membrane penetration function for movement of the RNAi polynucleotides from outside the cell to inside the cell. Reversible modification provides physiological responsiveness to the delivery peptides.
First claim
Opening claim text (preview).
We claim: 1. A peptide comprising the amino acid sequence of Seq ID 2, Seq ID 3, Seq ID 4, Seq ID 5, Seq ID 6, Seq ID 7, Seq ID 8, Seq ID 9, Seq ID 10, or Seq ID 11. 2. The peptide of claim 1 wherein the peptide consists of L-form amino acids. 3. The peptide of claim 1 wherein the Melittin peptide contains at least one D-form amino acid. 4. The peptide of claim 1 wherein at least one targeting ligand is linked to an…
Assignees
Inventors
Classifications
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9526796B2 cover?
- The present invention is directed compositions for targeted delivery of RNA interference (RNAi) polynucleotides to hepatocytes in vivo. Targeted RNAi polynucleotides are administered together with co-targeted melittin delivery peptides. Delivery peptides provide membrane penetration function for movement of the RNAi polynucleotides from outside the cell to inside the cell. Reversible modificati…
- Who is the assignee on this patent?
- Arrowhead Madison Inc, Arrowhead Pharmaceuticals Inc
- What technology area does this patent fall under?
- Primary CPC classification C12N15/111. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Dec 27 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).